Ceftazidime
- Catalog NO.:A936728
- CAS No. : 72558-82-8
- Molecular Formula:C22H22N6O7S2
- Molecular Weight: 546.58
Note*
1. Please click the to confirm the discount and stock quantity.
2. Click“Bulk Inquiry”to ask for quotations of other quantity.
3. The price does not include shipping and bank charges.
Bulk Inquiry
1. Please click the to confirm the discount and stock quantity.
2. Click“Bulk Inquiry”to ask for quotations of other quantity.
3. The price does not include shipping and bank charges.
Quality Control&SDS
Product Details
CAS Number | 72558-82-8 | Appearance | |
Catalog Number | A936728 | MDL Number | MFCD00072034 |
Molecular Formula | C22H22N6O7S2 | Molecular Weight | 546.58 |
Boiling Point | Melting Point | ||
Flash Point | Density | ||
Synonyms | (6R,7R)-7-((Z)-2-(2-Aminothiazol-4-yl)-2-(((2-carboxypropan-2-yl)oxy)imino)acetamido)-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate | ||
Storage Condition | Store in a tightly closed container,in a cool and dry place |
Safety
GHS Pictogram | |||
Signal Word | Danger | UN Number | 2811 |
Hazard Statements | H317-H319-H334 | Class | 6.1 |
Precautionary Statements | P261-P280-P305+P351+P338-P342+P311 | Packing Group | Ⅲ |
Description
Ponatinib, also known as AP24534 is an oral drug for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL). It is a multi-targeted tyrosine-kinase inhibitor. Some forms of CML, those that have the T315I mutation, are resistant to current therapies such as imatinib. Ponatinib has been designed to be effective against these types of tumors. Ponatinib was approved in 2012. |